1M6MYTD1Å5ÅMAKS.
Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Nyheder Til nyhedsfeedet
Curatis increases revenue in first half by 51% and reduces loss
Curatis raised net revenue in H1 2026 by 51% to CHF 7.9 million, with product sales of CHF 7.4 million and service sales of CHF 0.6 million. The deficit shrank to CHF 0.4 million after −CHF 1.2 million the previous year, and cash and cash equivalents rose to CHF 3.6 million thanks to a convertible instrument placed in May for CHF 3 million. For 2026 the biotech company confirms the revenue guidance raised in June of around CHF 15 million and aims for a breakeven result. For its key project Corticorelin (C-PTBE-01), a meeting with the FDA to define the Phase‑III study design is planned for Q1 2027. » Mere på finanzen.net
Virksomhedstal
| (EUR) | juni 2026 | |
|---|---|---|
| Omsætning | 8,6 mio. | - |
| Bruttofortjeneste | 268,67 t | - |
| Nettoresultat | -440,92 t | - |
| EBITDA | -226,42 t | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 106,2 mio. € |
Antal aktier | 5,3 mio. |
Højeste/laveste i 52 uger | 29,57 € - 11,71 € |
| Udbytte | Nej |
Beta | -0,81 |
P/E (PE Ratio) | -148,70 |
PEG (PEG Ratio) | 5,00 |
K/I (PB Ratio) | 2,01 |
P/S (PS Ratio) | 7,42 |
Virksomhedsprofil
| Navn | Curatis Holding AG |
| CEO | Roland Rutschmann |
| Medarbejdere | 9 |
